Mannkind Corp (MNKD): Rosabel Realica Alinaya , SVP, Prin Acctg Officer of Mannkind Corp sold 6,294 shares on Jul 6, 2016. The Insider selling transaction was reported by the company on Jul 18, 2016 to the Securities and Exchange Commission. The shares were sold at $1.06 per share for a total value of $6,671.64 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2016, Michael Castagna (Chief Commercial Officer) purchased 50,000 shares at $0.93 per share price.On May 26, 2015, Juergen Martens (COO) purchased 20,000 shares at $4.57 per share price.Also, On Apr 27, 2015, Hakan Edstrom (President & CEO) sold 73,460 shares at $4.83 per share price.On Feb 23, 2015, David Thomson (VP & General Counsel) sold 68,662 shares at $7.19 per share price.
Shares of MannKind Corporation (MNKD) ended Friday, Jul 15, 2016 session in red amid volatile trading. The shares closed down -0.02 points or -1.94% at $1.01 with 33,45,917 shares getting traded. Post opening the session at $1.03, the shares hit an intraday low of $0.9911 and an intraday high of $1.04 and the price vacillated in this range throughout the day. The company has a market cap of $433 M and the number of outstanding shares has been calculated to be 42,91,61,350 shares. The 52-week high of MannKind Corporation is $5.8 and the 52-week low is $0.6426.
Company has been under the radar of several Street Analysts.MannKind Corporation is Reiterated by RBC Capital Mkts to Underperform and the brokerage firm has raised the Price Target to $ 0.20 from a previous price target of $0.15 .The Rating was issued on May 10, 2016.MannKind Corporation is Reiterated by Piper Jaffray to Underweight and the brokerage firm has raised the Price Target to $ 0.10 from a previous price target of $0.05 .The Rating was issued on May 10, 2016.
MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The Company’s product candidate is AFREZZA inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Company’s Technosphere powders are -based on the Company’s fumaryl diketopiperazine (FDKP) which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury Connecticut facility.